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Targeting particular cells or tissues for imaging e.g. proliferative cells or for 
transporting drug molecules plays a vital role in cancer treatment and represents an area 
of high scientific interest. In order to contribute to a better detection of proliferative cells, 
a sophisticated metal-DOTA imaging agent was designed that is able to specifically 
interact with disulfide bridges of proteins by intercalating into accessible disulfide 
bridges via two sequential Michael addition-elimination reactions. Such DOTA-protein 
conjugates are highly versatile since they can be labeled with 68Ga for PET or 
paramagnetic metals such as Gd(Ⅲ) for MR imaging. 
In addition, a folate-metal-DOTA conjugate has been prepared as well as a novel 
approach that facilitates somatostatin-metal-DOTA conjugates has been designed for 
targeted delivery and first attempts have been undertaken to achieve this challenging goal. 
Folic acid or somatostatin-DOTA conjugates require conjugation via a tailored linker. 
The synthesis of this linker moiety, the functionalization of the metal-DOTA complex 
and the conjugation approach is thoroughly investigated. Based on this strategy, site-
directed labeling of peptides or even larger proteins with a single accessible disulfide 




vivo evaluation of the Folic acid-DOTA derivative. In addition,  a larger number of 
gadolinium complexes may be attached to proteins with multiple disulfide bridges which 










Chapter 1.  Introduction 
 
1.1. Metal Complex for MRI or PET 
 
Molecular imaging is one of the most exciting and rapidly growing areas of 
science as it enables the characterization and quantification of biological processes at the 
cellular and subcellular level in living subjects in an intact manner[1]. It utilizes specific 
molecular probes as well as intrinsic tissue characteristics as the source of image contrast, 
and offers the opportunity for an improved understanding of integrative biology, earlier 
detection and characterization of diseases, and facilitates a better evaluation of 
therapeutic treatment[2]. The imaging modalities can be broadly divided into two 
categories: anatomical and molecular techniques. Examples of anatomical imaging 
technologies include computed tomography (CT) and magnetic resonance imaging (MRI), 
which are characterized by high spatial and temporal resolutions. On the other hand, 
molecular techniques such as positron-emission tomography (PET) and single-photon-
emission computed tomography (SPECT) offer excellent sensitivity and often provide 
important biochemical information on pathological conditions [3, 4].  
 
 






Figure 1. The structure of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA) and folic acid 
 
In molecular imaging techniques, the contrast media play an important part in 
improving the sensitivity, resolution of images and target specificity at the 
molecular/cellular level.  However, the toxicity of the contrast agent is a major concern in 
its application. For example, lanthanide ions are widely used as MRI contrast agents[5], 
radioactive tracers[6], and optical imaging probes[7, 8]. Nonetheless, free lanthanide ions 
often exhibit high toxicity in vivo. To circumvent this problem, chelating agents are 
extensively used to coordinate to these metal ions and thus minimize their toxicity. 
Among various chelating agents, macrocyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA) (Figure 1) is one of the widely used ligand in molecular imaging 
as it outperforms other agents in  the ability to form complexes with a large number of 
transition and lanthanide metal ions with high thermodynamic stability and kinetic 
 
 





inertness[9]. DOTA complexes, depending on the metal ions, are mainly used in three 
areas: magnetic resonance imaging [Gd(Ⅲ), Eu(Ⅲ)], nuclear imaging[111In(Ⅲ), 68Ga(Ⅲ), 
64/67Cu(Ⅱ)], and therapeutic radiopharmaceuticals [90Y(Ⅲ), 177Lu(Ⅲ)]. Low–molecular-
weight contrast agents for MRI, such as the commercial agent Gd3+-DOTA (DotaremTM) 
display low relaxivity and extremely fast excretion rates in vivo. To improve the 
relaxivity, Gd(Ⅲ) chelates are conjugated to macromolecules, like proteins[10], micellar 
aggregates[11], dendrimers[12], or liposomes[13], thus extending the rotational 
correlation lifetime. But most of them are not able to differentiate between “healthy” and 
e.g. tumor cells thus preventing cell or tissue-specific molecular imaging. Nonetheless, 
remarkable progress has been made in recent years in the development of targeted 
contrast agents for diagnostic imaging that allows better differentiation [14, 15]. Various 
targeted contrast agents for MRI and PET have been reported which were synthesized via 
the  conjugation of metal chelates to various biomolecules, including peptides[16], 
proteins[17], antibodies[18], oligonucleotides[19] and biotin/avidin[20]. These 
biomolecules are used as molecular imaging probes which show high binding affinity to 
the target receptors, antigens, and nucleic acids being specifically overexpressed in or on 
the targeted cells tissues.  
 
 








1.2. The Biological Function of Folic Acid 
 
Folic acid(Figure 1) is a water-soluble vitamin of the B-complex group and plays 
essential roles in numerous bodily functions by participating in the biosynthesis of 
nucleic and amino acids [21]. More importantly, it can be utilized for targeted delivery. 
Targeted delivery via selective cellular marker improves the efficacy and safety of 
the therapeutic and imaging agents.  Among cellular surface targets, folate receptors 
(FR)-α is most promising and well-investigated in epithelial cancers. The other form of 
FR (FR-β) is present in myeloid leukemia and activated macrophages, increasingly 
recognized as a cellular target[22]. A variety of molecules including radioimaging agents, 
magnetic resonance imaging (MRI) contrast agents, chemotherapeutic agents, 
oligonucleotides, proteins, enzyme constructs for prodrug therapy, haptens, liposomes, 
nanoparticles and gene therapy vectors have been conjugated to folate for FR-targeted 
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contrast[28]. The folic acid and receptor pair fulfill most of these requirements; hence 
they are an attractive ligand/receptor combination for targeted imaging.  
Folate-targeted conjugates of radionuclides (Figure 3), like 99mTc[29-31], 111In[32, 
33], 66/67/68 Ga[34, 35] and 18F[36], for SPECT and PET imaging have been developed 
and evaluated in preclinical and clinical studies. In addition, a few folate-targeted MRI 
contrast agents have also been reported [37, 38].  
 
 
Figure 3. [18F]-FDG microPET (middle), MR (right), and [66Ga]Ga-DF-Folate microPET 
(left) images of mice with subcutaneous folate-receptor-positive human KB cell tumor 
xenografts in their intrascapular region[39].  
 
1.3       The Biological Significance of Somatostatin 
 
Somatostatin(Figure 4) is a cyclic tetradecapeptide hormone. It is found in 





















































































techniques and in vitro autoradiography on a variety of human tumors, such as pituitary 
tumors, endocrine pancreatic tumors, carcinoids, paragangliomas, meningiomas, brain 
tumors (astrocytomas), neuroblastomas, and some human breast cancers[41]. Therefore, 
somatostatin/somatostatin receptor system is studied intensively in contrast-enhanced 
diagnostic imaging and targeted therapy of tumors. The exact mechanism of somatostatin 
antineoplastic activity is unknown, but some possibilities are: (1) a direct antiproliferative 
effect by blockade of mitogenic growth signal or induction of apoptosis through 
interaction with somatostatin receptors; (2) inhibition of secretion of gastrointestinal 
hormones thought to be important in tumor growth; and (3) reduction or inhibition of 
secretion of growth-promoting hormones and growth factors which stimulate the growth 
of cancers[42].  
A major progress is made by introducing radiolabelled somatostatin for diagnosis 
and treatment of cancers. Somatostatin acts as a bullet to specifically target a maligant 












1.4. Chemical Modification of Proteins 
 
There is an increasing interest in protein conjugates for diagnosis and therapy. 
Even though proteins often display limited pharmacokinetics, low proteolytic stabilities 
and the possibility to elicit immune responses, there have been successful attempts of 
converting  proteins into  efficient drug delivery systems or imaging agent [43]. Their 
low nanometer sizes, highly defined structures, biodegradability and the presence of a 
high number of functional groups available for chemical modifications make them 
attractive for applications in targeted drug delivery and bioimaging. 
 
 
Figure 5. (a) Site-specific modification of protein yields homogenity and (b) non-
specifcification modification of protein results heterogeneity[44] 
 
 






Protein conjugates can be prepared via chemical modification and bioengineering 
techniques. Chemical modification approaches can be divided into two major categories; 
site-specific and non-specific protein functionalization(Figure 5).   
Classical non-specific protein conjugation techniques typically involve 
electrophilic reagents targeting the nucleophilic functional groups of lysine (Scheme 1), 
cysteine, aspartic acid or glutamic acid side chains, generally providing a heterogeneous 
mixture of proteins modified to a different extent and at variable locations in the protein 
conjugates[44, 45].  
A more specific strategy represents the modification of cysteine residues (Scheme 
1) through alkylation with iodoacetamide reagents, disulfide exchange and Michael 
addition with maleimides[46-48]. Since free cysteine groups are rare and often 
inaccessible, they can be engineered into the protein as point mutations using molecular 
biological techniques. Such approaches are usually demanding and expensive and point 
mutation may have a negative impact on protein function by altering its structure. 
Moreover, introducing an accessible free thiol group often leads to disulfide scrambling, 
protein misfolding and an increased tendency to form aggregates during purification. Still, 
 
 





thiol-specific modifications play an important role due to the potential for high-yield 
reactions (e.g. Michael reactions), as well as the propensity for addressing cysteine 
groups selectively without targeting other amino acids.  
 
 
Scheme 1. Non-specific modification of a) lysines and b) cysteines residue on proteins 
 
In recent years, significant progress has been made to develop improved strategies 
for selective and efficient protein chemistry and thus more well-defined protein 
conjugates[47, 48].  New means have been established for the modification of tyrosine 
and tryptophan, usually by applying transition-metal-mediated processes that are 
 
 





compatible with aqueous conditions[45]. Tyrosine residues are modified via a three-
component Mannich reaction with aldehydes and anilines[46, 49]. Targeting tryptophan 
residues has been developed by employing rhodium carbenoids in acidic condition (pH≈
2), which may affect the structure of some protein[50]. As hydrophobic amino acids are 
generally buried within the protein scaffold, controlled single-site modification of 
tyrosines and tryptophans is possible in some cases by improving surface accessibility 
often via point mutations[51].  
Probably the most elaborate method to site-specifically modify proteins involves 
the introduction of non-canonical amino acids (rNCAA) into proteins[45]. Here, by 
chemically attaching the desired rNCAA to suppressor tRNA and then placing the amber 
codon at the desired position in the mRNA, a number of rNCAA have been incorporated 
at different positions into the protein sequence. Successful examples of rNCAA that are 
incorporated into the protein sequence include p-iodotyrosine, which undergoes Pd-
catalyzed alkenylation ( Mizoroki-Heck reaction ) or alkynylation ( Sonogashira reaction ) 
reactions from the protein surface[52],  Stille coupling using organotin derivatives as well 
as Suzuki reactions utilizing boronic acids and esters[45]. Previously, rNCAA with an 
azido or  ethynyl group has been incorporated into different proteins[53]. Azide-alkyne 
 
 





[3+2] cycloaddition are conducted in the presence of Cu (I) as catalyst, yielding 
exclusively the 1,4-substituted triazole isomer. These reactions proceed rapidly in water, 
and provide excellent chemoselectivity and regioselectivity [53].  
 
1.5. Site-specific Intercalation into Proteins using a Three-Carbon Bridge 
 
1.5.1 Disulfide Bonds in Therapeutically Relevant Proteins 
 
In general, free and accessible cysteine residues are rare[54] and liable to pair up 
to form disulfides bridges [55, 56]. Disulfide bonds influence the physio-chemical and 
biological properties of proteins in many subtle and complex ways[57]. They are either 
buried within the protein’s folding region or on its solvent accessible surface[58]. 
Solvent-accessible disulfides can be selectively approached by tailored reagents and can 
be chemically modified. As accessible disulfides primarily contribute to the stability of a 
protein rather than to its structure or biological function[59] it is feasible to intercalate 
into this bond by tailored reagents without a loss of either structure or function. 
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Consequently, the two free cysteine sulfur atoms are available for chemical modification 
for instance, via Michael addition reactions.  
After the mild reduction of the accessible disulfide in a native protein, the two 
free thiol groups are ready for the site-specific intercalation (in case the protein offers just 
a single accessible disulfide bridge). Generally, the intercalating reagents comprise of an 
electron-withdrawing group (e.g., carbonyl group), an α,β-unsaturated double bond and 
a α ,β ’sulfonyl group that is susceptible to elimination as sulfinic acid[61].  The 
conjugated double bond in the mono-sulfone allows for a sequence of interactive and 
sequential addition-elimination reactions[61]. (Scheme 2) 
The site-specific intercalation into a disulfide bond differs from other thiol-
specific modifications. For the commonly used methods, each sulfur react separately and 
independently with di-thiol reagents; while the two cysteines of the original disulfide 
bond are covalently reconnected through a three-carbon methylene bridge. Since other 
reagents used to modify disulfides like two maleimides or two vinyl sulfones are 
chemically independent, they cannot undergo controlled bis-alkylation by sequential 
addition-elimination reactions[60]. In addition, this method of using a intercalating agent 
is highly attractive since it is crucial to preserve a protein’s tertiary structure after a mild 
 
 





reduction of an accessible disulfide to (i)  allow the free thiol groups to be spatially close 
to each other, (ii) minimize any chance of  the irreversible denaturation and aggregation 
of the protein, and (iii) prevent disulfide scrambling reactions if more than one disulfide 
bond is reduced[61].  
 
1.6. Design of biocompatible metal-complex protein conjugates 
  
In order to design biocompatible metal-complex protein conjugates which can 
achieveprecise intracellular delivery and improved sensitivity for imaging, two 
components are required, namely, an imaging agent and an efficient targeting entity. 
There are several strategies that can be adopted. One of which is the mono-
functionalization of DOTA, followed by the combination of an imaging group and a cell 
targeting moiety via amide bond formation.  The other method is the synthesis of a 
tailored linker which can intercalate into the cell targeting entity. Then the two parts can 
be combined via click reaction or Michael addition. As a targeting unit, folic acid 
interacts with folate receptors that are overexpressed in certain cancer cell lines. Similarly, 
somatostatin interacts with G-protein-coupled somatostatin receptors. Metal-DOTA and 
somatostatin could be conjugated via a tailored linker as outlined in the second method. 
DOTA-Folate (Scheme 7, 8) and DOTA-somatostatin (Scheme 14) conjugates will be 
prepared, and their biological properties will be investigated via in vitro experiments. 
 
 





When 68Ga labeled conjugates have been synthesised, the tracers can be studied via PET 
using small animal models, such as rats, implanted with tumor cells. The PET 
biodistribution data can be obtained and compared with other imaging modes. Similarly, 
MR imaging can also be achieved by labeling the conjugates with paramagnetic metals 
Gd(Ⅲ). Based on this strategy, labeling of larger proteins bearing several disulfide bonds 
will be explored in order to attach a larger number of gadolinium or gallium complexes 









Chapter 2. Project Aim and Design 
(Ⅲ) (Ⅲ)  
Figure 6. The bifuncional molecule consisting DOTA complex and folic acid 
 
The aim of my project is to synthesize novel bifunctional molecules that allow 
imaging via a DOTA unit connected to a cell targeting folic acid group. The bifunctional 
molecule consisting of the DOTA complex and folic acid moiety is shown in Figure 6. 
Considering that folic acid is only limited to certain cancer cell lines and that generally, 
proteins such as antibodies and peptides such as somatostatin also represent attractive 
entities allowing targeted delivery. The final structure of the bifunctional molecule 
consisting DOTA complex and somatostatin is shown in Figure 7. However, the defined 
and ideal site-directed functionalization is a key concern. Therefore, the disulfide site 

































































































Chapter 3. Results and discussion 
 
3.1 Synthesis of 1, 4, 7-tris (tert-butoxycarbonylmethyl)-1, 4, 7, 10-












































Scheme 3. Synthesis of tri-tert-butyl 2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetate (DO3tBu) 
 
To efficiently attach the DOTA chelator to biomolecules, it should be 
functionalized with a reactive group that allowed covalent bond formation to the 
biomolecules. Since amine groups are abundant in biomolecules, and the conversion of a 
pendant carboxylic acid of DOTA into a carboxamide minimally affected the stability of  
 
 





the conjugating metal complex, a straightforward approach would be to the conjugation 
of DOTA derivatives to biomolecules through a physiologically stable amide bond[40]. 
In this context, the synthesis of DOTA-monoamide derivatives by an efficient strategy 
was the main focus. The synthesis of 1, 4, 7-tris (tert-butoxycarbonylmethyl)-1, 4, 7, 10-
tetraazacyclododecane (DO3tBu) (3) was described in this section. 
In the initial trials, chloroform and triethylamine were used as the solvent and 
base respectively (Scheme 3). According to literature, triethylamine exhibited greater 
steric hindrance and would lead to tri-substituted cyclen as a main product [62]. On the 
contrary, analysis with the LC-IT-TOF-MS spectra (Appendix 29) indicated that the 
reaction mixture contains comparable quantity of 3, 4 and 5, indicating that the selected 
reaction condition was not optimal for achieving selectivity. Furthermore, the side 
product 5 could not be separated from the target molecule, 3, even after column 
chromatography, as indicted in the ESI-MS spectrum. 
Hence, a different protocol was attempted by using acetonitrile as solvent and 
sodium bicarbonate as base (Scheme 4). The reaction mixture was monitored using LC-
IT-TOF-MS (Appendix 29). The spectrum obtained indicated that this approach was also 
lacking in terms of selectivity, and significant amount of by-products 4 and 5 were 
 
 





formed. The pure compound 3 was obtained by column chromatography using 
CDCl3/MeOH= 10:1, while the use of DCM/MeOH=10:1 couldn’t afford the desired 
separation. 
  
3.2 Synthesis of Tert-butyl 2, 2’, 2’’-(10-(2-oxo-2-(prop-2-ynylamino) ethyl)-1, 4, 
7, 10-tetraazacyclododecane-1, 4, 7-triyl) triacetate (8) 
 
Scheme 5  Synthesis of tert-butyl 2,2',2''-(10-(2-oxo-2-(prop-2-ynylamino)ethyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (8) 
 
An alkyne-functionalized DOTA derivative 8 (Scheme 5) was prepared since it 
could specifically label azido-modified biomolecules by Cu(Ⅰ ) catalyzed [3+2] 
cycloaddition (click chemistry).  The purification of compound 8 was non-trivial, as the 
spot of compound 8 could not be resolved from the side product on the TLC plate. The 
 
 





spot of compound 8 could be confirmed by staining with KMnO4 or I2, whereas the side 
product could only be stained by I2.  Therefore, the yield of 8 from this reaction was low. 
Both the 1H NMR spectrum and 13C NMR spectra of compound 8 were in agreement 
with the literature [63]. 
 
3.3 Synthesis of tert-butyl 2, 2’-(4-(2-tert-butoxyallyl)-10-(6-(2, 5-dioxo-2, 5-










































Scheme 6. Synthesis of DOTA-maleimide deriveritives (10) 
 
In some cases, site-specific labeling of cysteine resides of proteins via Michael 
addition was feasible, and therefore, an additional maleimide functionalized DOTA 
 
 





derivative 10 was prepared (Scheme 6). When EDC and DMAP were added to compound 
9 dissolved in DCM, the color of the solution changed from colorless to pink. This 
indicated the possibility of a side reaction which formed a colored impurity. 
 
3.4 Preparation of DOTA-Folate Conjugate 
 
 










Scheme 8. The second route to synthesize Folate-DOTA conjugate 
 
Schemes 7 and 8 elaborated two facile ways to synthesize folate-DOTA 
conjugates and the biological evaluation of these bifunctional molecules are currently in 
progress. All the reactions were monitored using LC-IT-TOF-MS. The molecular mass of 
folic acid and Folate-NHS (11) corresponded to 441 g/mol and 538 g/mol. The LC profile 
indicated that the Folate-NHS derivative 11 was formed since a signal at 538 g/mol was 
observed. The major component detected corresponds to folic acid. However, since 
 
 





folate-NHS could be easily hydrolyzed in the LC conditions, it is highly plausible that the 
content of Folate-NHS (11) was under-estimated. For further reactions, excess of the 
Folate-NHS containing some folic acid was used.  
The main problem with the folate derivatives was their poor solubility in most 
organic solvents. They were soluble in DMSO and sparingly soluble in DMF; therefore 
conventional normal phase column chromatography was ineffective. Preparative reversed 
phase HPLC was used instead to isolate the products. 
 
3.5 Synthesis of Tailored Linker (16) 
 









The tailored linker, 16, could specifically intercalate into disulfide bridges of 
proteins via two consecutive Michael addition reactions and the synthesis is depicted in 
Scheme 9. The linker could also be modified with additional functionality to allow for a 
covalent linkage to metal chelates.  
The oxidation from bis-disulfide 15 to bis-disulfone could also be achieved by 
using H5IO6 and CrO3 (Scheme 10) and both methods of oxidation were attempted. 
 
Scheme 10. Alternative method to convert bis-disulfide to bis-disulfone (16) 
 
The reaction of 15 with  H5IO6 and CrO3 was monitored by cospotting with bis-
disulfone and bis-disulfide on TLC (Hexane/EA=1:1). On the TLC, the reaction mixture 
had three spots which correlate in terms of retention factor to a mixture of the starting 
material 15, reaction intermediate 17 and the product 16 indicating that the oxidation was 
incomplete.  In comparison, oxidation utilizing oxone does not form the intermediate 17 










3.6        Synthesis of Water Soluble Intercalator (21) 
 
Since the intercalation to biomolecules has to be in aqueous condition and the 
water solubility of the mono-sulfone affected the rate and efficiency of the intercalation, 
intercalators with improved water solubility had been designed. Here, bis-disulfide 15 
was modified and a piperazine group was introduced which could be protonated in order 
to achieve improved water solubility (Scheme 11). The modification was performed on 
the compound 15 since the bis-disulfide is more stable than the bis-disulfone, 16. 
 
 









In the synthesis of compound 18, the ESI-MS spectrum showed a major mass peak of 462 
which suggests that the alkyl bromide was labile under the reaction condition and had 
dissociated to form compound 22 (Figure 9). The FAB-MS spectrum displayed two peaks, 
462 and 565 which proves that the alkyl bromide is labile.  
 
 
Figure 9: The side product in the synthesis of compound 18 
 
 The reaction route was modified as shown below (Scheme 12). Bis-disulfide 15 
was reacted directly with 2-piperazinoethylamine under standard HBTU coupling 










Scheme 12. The second synthetic route towards the water soluble intercalator (21) 
 
When bis-disulfide 15 was converted to compound 23, the product was monitored 
by TLC (Hexane/EA =1:1).The major spot corresponded to a retention factor of 0.8 
which was unlikely to be the desired product. Upon analysing the reaction mixture using 
LC-IT-TOF-MS (Appendix 11), it was found that the desired piperazine bis-sulfide 23 
was formed as the minor product and in addition, the peaks were not well resolved under 
several eluting conditions. The low yield of the reaction could be attributed to the 
chemoselectivity of the coupling reaction towards the free primary and secondary amine 
groups. Therefore, the reaction was modified to carry with the additional protection of the 
2-piperazinoethylamine as shown below (Scheme 13).  
 
 






Scheme 13. The third synthetic route of water soluble intercalator (21) 
 
In the attempt to synthesize compound 26, several different conditions were attempted 
but the selectivity of the protection was not achieved.  
 
3.7 Intercalation of Somatostatin 
 
Somatostatin was found to interact with G-protein-coupled somatostatin receptors 
which were abundant in various tumours, notably neuroendocrine tumours of which 
cacinoid tumour and phaeochromocytoma were encountered most in the clinical practice. 
 
 





The bifunctional linker, 15, was designed to conjugate to both the metal DOTA complex 
and somatostatin(Scheme 14). In this project, the linker 15 was successfully conjugated 
to DOTA giving compound 31, which should be subsequently converted to the bis-
disulfone for intercalation into the somatostatin. However, compound 31 was unstable in 
the oxidation condition and degraded during the reaction.  
 
Scheme 14. Intercalation of Somatostatin 
 
 





Chapter 4. Experimental 
 
4.1       General Procedures 
 
Unless otherwise noted, all operations were performed without taking precautions 
to exclude air and moisture. All solvents and reagents were purchased from commercial 
sources and were used without further purification. Reaction progress was monitored by 
thin layer chromatography (TLC) using Merck 60 F254 pre-coated silica gel plates 
illuminating under UV 254nm or using appropriate stains. Flash column chromatography 
was carried out using Merck silica gel 70-230 mesh. NMR spectra were measured on a 
Bruker ACF 300 and AMX 500 spectrometers and the shifts were referenced to residual 
solvent shifts in the respective deutero solvents. Chemical shifts are reported as parts per 
million referenced with respect the residual solvent peak. Mass spectra were acquired on 
a Finnigan Mat 95XL-T or a Finnigan Mat LCQ (ESI) spectrometer.LC-MS analysis was 










4.2  Synthesis of 1, 4, 7-tris (tert-butoxycarbonylmethyl)-1, 4, 7, 10-













































Procedure 1 [64] 
Tert-butylbromoacetate (198 mg, 1.016 mmol, 3.5equiv) dissolved in 3mL of 
anhydrous chloroform was added dropwise to a mixture of 1,4,7,10-
tetraazacyclododecane (cyclen) (50.0 mg, 0.2902 mmol, 1equiv) and  triethylamine (294 
mg, 2.902 mmol, 10equiv) in 5 mL of anhydrous chloroform under argon atmosphere. 
The reaction mixture was stirred for a further 20 h. The resulting solution was washed by 
water, and the organic phase was dried by Na2SO4. The solvent was removed, and the 
crude products was purified by column chromatography (DCM/MeOH=10:1). After 
 
 





purification, the product was still a mixture, containing the desired product (3) and tetra-
tert-butyl 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetate (5). 
ESI-MS (MeOH, 250oC): (+) m/z = 515[3+H], 651[5+Na]. 
 
Procedure 2: [65] 
Under argon atmosphere, cyclen (210 mg, 1.3 mmol, 1equiv) and sodium 
bicarbonate (350 mg, 4.2 mmol, 3.23equiv) were mixed in 150ml acetonitrile. Then, tert-
butyl bromoacetate (820 mg, 4.2 mmol, 3.23equiv) in 50ml acetonitrile was added 
dropwise at RT for a period of 30 min. The reaction mixture was refluxed for 24 h at 
87 ℃. The resulting precipitate was filtered and the solvent was evaporated. The crude 
product was first purified by recrystallization from toluene. A white powder was obtained 
and purified by column chromatography using chloroform/MeOH (v/v=10:1) as eluting 
solvent. 1, 4, 7-tris (tert-butoxycarbonylmethyl)-1, 4, 7, 10-tetraazacyclododecane 
(DO3tBu) (3) was isolated in 64% yield. 
 
 





1H NMR (500MHz, CDCl3): δ 3.2402 (s, 4H), 3.1494 (s, 2H), 2.9540 (br s, 4H, ring-
CH2), 2.7825 (br, 8H, ring-CH2), 2.7271 (br, 4H, ring-CH2), 1.3088 (s, 27H, Boc); 
(Appendix 14) 
13C NMR (500MHz, CDCl3): δ 28.19, 28.24, 47.51, 49.26, 51.40, 58.23, 81.69, 81.84, 
169.63, 170.51; (Appendix 15) 
ESI-MS (MeOH, 250oC): (+) m/z= 515 [M+H]; (Appendix 16) 
 




Aqueous 0.1M NaOH (4 ml) was poured on top of a solution of propargylamine 
(0.4 ml, 5.83 mmol) in 20ml DCM. Then, bromoacetyl chloride (6 ml, 18.7 mmol) was 
added by a syringe into the DCM layer, causing the immediate formation of a brown 
precipitate. The brown mixture was stirred vigorously for 2.5 h at RT during which time 
the precipitate re-dissolved. After the reaction was finished, the reaction solution was 
transferred to a separator funnel with excess DCM and water. The aqueous layer was 
 
 





isolated and extracted with DCM (5*10 ml). All organic fractions were combined and 
washed with 50 mM sodium carbonate (3*10 ml). The solution was dried by anhydrous 
magnesium sulfate and the solvent was removed under vacuum to form brown solid with 
26 % yield. 
1H NMR (500MHz, CDCl3): δ 6.6396(s, 1H, NH), 4.0925(q, 2H, 2.67MHz, CH2NH), 
3.8992(s, 2H, CH2Br), 2.2803(t, 1H, 2.64MHz, triple bond hydrogen); (Appendix 17) 
ESI-MS (MeOH, 250oC): (-) m/z=175[M-H]; (Appendix 18) 
 
4.4 Synthesis of Tert-butyl 2,2',2''-(10-(2-oxo-2-(prop-2-ynylamino)ethyl)-1,4,7,10-




A solution of DO3tBu 3 (59 mg, 0.1146 mmol), N-(2-propynyl)bromoacetamide 
(20 mg, 0.1146 mmol) and K2CO3 (16 mg, 0.1146 mmol) in DMF (1.2 ml) was stirred 
under argon at r.t. for 2 h. After removal of the solvent in vacuo, the residual mixture was 
 
 





purified by silica gel column using chloroform/methanol = 95： 5 → 9： 1. The 
compound 8 was isolated in 47% as brown solid. 
13C NMR (500MHz, CDCl3): δ172.30，171.93， 81.87， 80.86， 69.55， 56.10， 
56.01， 55.70， 55.61，28.51，27.97，27.89; (Appendix 19) 
ESI-MS (MeOH, 250oC): (+) m/z =632 [ M + Na ]; (Appendix 20) 
 

















6-aminohexanoic acid (0.669 g, 5.1 mmol, 1equiv) and maleic anhydride (0.5 g, 
5.1 mmol, 1equiv) in acetic acid (20 ml) were stirred at r.t. for 15 h under argon. The 
resulting white suspension was then heated to 150℃ for 8 h (white suspension was 
dissolved). The solvent was removed in vacuo, and the residue was purified by silica gel 
column chromatography (CHCl3: MeOH = 100:1.5). The crude product then was 
 
 





dissolved in DCM and extract by DI water three times to remove residual acetic acid. 591 
mg of white solid 12 was isolated corresponding to 59% yield. 
 
Procedure 2 
6-Aminohexanoic acid (1.34 g, 10.2 mmol) was added to a stirred solution of 
maleic anhydride (1 g, 10.2 mmol) in acetic acid. A white solid precipitated immediately 
and stirring was continued for 3 h at room temperature. The solid was collected by 
filtration. Without further purification, the product was mixed with 9 ml of acetic 
anhydride (9 ml). Sodium acetate (0.441 g, 5.38 mmol) was added and the reaction 
mixture was heated to 90℃ for 2 h. The solvent was removed under reduced pressure and 
the residue was dissolved in ethyl acetate (20 ml). The solution was washed with water 
(20 ml) followed by brine (20 ml) and the organic layer was dried over sodium sulfate. 
The solvent was removed by evaporation to provide an off-white solid, which was 
purified by short column chromatography (EtOAc: Hexane = 1:1) to give 6-
maleimideocaproic acid as a white solid. The yield was 65 %. 
1H NMR (500MHz, CDCl3): δ6.69(s, 2H), 3.52(t, 2H, 6.95Hz), 2.35(t, 2H, 7.25Hz), 
1.67(q, 2H, 7.77Hz), 1.61(q, 2H, 7.57Hz), 1.34(m,2H); (Appendix 21) 
 
 





13C NMR (500MHz, CDCl3): δ178.60, 170.84, 134.07, 37.59, 33.59, 28.16, 26.12, 24.10; 
(Appendix 22) 
 
4.6 Synthesis of Tert-butyl 2, 2’-(4-(2-tert-butoxyallyl)-10-(6-(2, 5-dioxo-2, 5-dihydro-





To 6-maleimideocaproic acid 9 (25 mg, 0.1166 mmol, 1.2 equiv) dissolved in 1ml 
of DMF HBTU (59 mg, 0.1554 mmol, 1.6 equiv) and DIEA (32 µl, 0.1943 mmol, 2 
equiv) were added at 0℃. The reaction mixture was stirred for 10 mins before DO3tBu 3 
(50 mg, 0.09714 mmol, 1 equiv) was added and the resulting mixture was stirred 
overnight at r.t. The solvent was reduced under high vacuum, and the product was 
dissolved in DCM. The organic phase was washed with NaOH, brine and dried over 
 
 





anhydrous Na2SO4. The solvent was evaporated under vacuum and the product was 
purified by column chromatography (CHCl3: MeOH = 10:1) yielding 27 mg (40 %) of 10. 
 1H NMR (500MHz, CDCl3): δ6.67(s, 2H), 3.64(t,2H), 3.51(m, 4H), 3.30(m, 6H), 2.99(t, 
2H), 2.89(s, 2H), 2.82(s, 2H), 2.75(s, 2H), 2.28(t, 2H), 1.62(m, 4H), 1.44(t, 27H), 1.32(m, 
2H); (Appendix 23) 
ESI-MS (MeOH, 250oC): (+) m/z= 708 [M+H]; (Appendix 24) 
 
4.7 Synthesis of Folate-NHS (11) 
 
Procedure: 
Folic acid (100 mg, 0.226 mmol) was dissolved in 6 ml of dry DMF to which 
DCC (31 mg, 0.152 mmol) and NHS (26 mg, 0.226 mmol) were added. The reaction 
mixture was stirred for 20 h at r.t. in the dark. The byproduct, dicyclohexylurea, was 
filtered off, and 30% acetone in diethyl ether (20 ml) was added under stirring. A yellow 
precipitate was formed and collected on a sintered funnel; after washing with acetone and 
 
 





ether several times, the folate-NHS 11 (109 mg) was isolated and characterized by LC-
IT-TOF-MS (Appendix 26). 
 




The folate-NHS (11, 50 mg, 0.09294 mmol) was dissolved completely in 20 ml of 
dry pyridine. 10 ml were taken from it to a RBF and then, DO3tBu (20 mg, 0.03886 
 
 





mmol) was added.  The mixture was stirred at r.t. in the dark for 48 h. After pyridine was 
evaporated, the resulting compound was dissolved in 3 ml TFA to remove BOC. 
Deprotection was carried out at r.t. for 4 h and thereafter, TFA was removed under 
vaccum[66]. The resulting compound was dissolved in DI water and 5 drops of TFA (5 
ml). The precipitate was filtered through a #4 Pyrex sintered glass funnel, the solution 
was collected and water was removed under high vacuum.  
Since folate-DOTA (13) is water-soluble in its protonated form, cation exchange 
chromatography was used for purification.  
 
Procedure of cation exchange chromatography 
Dowex resin (2 g) was added to a large glass chromatography column and the 
resin was conditioned by washing three times with 1 N NH4OH (15 ml), once with 500 
ml of water, once with 1 N HCl (15 ml) and once more with 500ml of water. The column 
eluent should be kept slightly acidic (pH 6–7). The crude folate-DOTA was dissolved in 
5 ml DI water with 2 drops of TFA and added to the column; the flowthrough was 
collected and passed over the column once more. Wash the column with 800 ml of water 
or until the pH of the eluent remains constant (pH 6–7). The Folate-DO3tBu was eluted 
 
 





from the column by adding 1 N NH4OH ( 50 ml). Aqueous NH4OH was removed using a 
rotary evaporator at 50℃ and 8mg of a light-brown solid was isolated and characterized 
by LC-IT-TOF-MS [67].   
LC-IT-TOF-MS (Appendix 27): (+) m/z= 770 [M+H] 
 




Folic acid (43 mg, 0.09714 mmol, 1 equiv) dissolved in 5 ml of DMF was 
combined with HBTU (59 mg, 0.1554 mmol, 1.6 equiv) and DIEA (32 µl, 0.1943 mmol, 
2 equiv) at 0 ℃. The reaction mixture was stirred for 10 min before DO3tBu (50 mg, 
 
 





0.09714 mmol, 1 equiv) was added. The resulting mixture was stirred again overnight at 
r.t.. Thereafter, the solvent was removed under high vacuum and the residue was washed 
with 10 ml acetone (30%) in ether, DCM (30%) in ether and water three times separately. 
The mixture was monitored by LC-IT-TOF-MS (Appendix 29). 
Time Percentage of acetonitrile 
0 to 10 min 0 % 
13 to 24 min 20 % 
30 to 33 min 30 % 
45 to 47 min 60 % 
52 to 60 min 100 %  
60 to 63 min 0 % 
Table 1 Eluting gradient used in Prep-HPLC. 
 
According to the LC profile, folate-DO3tBu (12) was successfully separated by 
GILSON Prep-HPLC (Waters XTerra Prep column, 5 µm 19*50 mm, 10 ml/min flow 
rate) by using water and acetonitrile as eluting solvents. The eluting gradient is shown in 















4-acetylbenzoic acid (500 mg, 3.045 mmol, 1 equiv), piperidine HCl (370 mg, 
3.045 mmol, 1 equiv) and paraformaldehyde (274 mg, 9.135 mmol, 3 equiv) were added 
to 2 ml absolute ethanol. To this solution, concentrated HCl was added (30 µl). Then the 
mixture was heated to 105℃ for reflux. After 4 h, paraformaldehyde (274 mg, 9.135 
mmol, 3 equiv) was added and the reaction was refluxed for further 6 h. Acetone was 
introduced into the reaction mixture to precipitate the product. Then the white precipitate 
was filter off and dried under the vacuum to afford the product (14) in 48% yield. 
1H NMR (300MHz, DMSO-d6):  δ 1.5–1.8 (6H), 3.23(s, 4H), 3.38 (t, 2H,), 3.69 (t, 2H), 
8.10 (m, 4H) (Appendix 1) 
ESI-MS (MeOH, 250oC): (-) m/z=260 [M-HCl] (Appendix 2) 
 
 









To a solution of ethanol (1.2 ml), methanol (0.8 ml), mannich salt (350 mg, 1.17 
mmol, 1 equiv) and 4-methylbenethiol (291mg, 2.348 mmol, 2 equiv) were added. Then 
piperidine (0.05 ml) and 37% (wt/vol) aq. formaldehyde 0.35 ml were introduced 
sequentially. The reaction mixture was heated to 105℃  for reflux. After 1 h, aq. 
formaldehyde (0.35 ml, 37 %, (wt/vol)) was added via a pipette through the top of the 
condenser. The reaction mixture was allowed to reflux for a further 3 h. The mixture was 
cool to RT and and then the solvent was evaporated at 40 °C. The resulting mixture was 
stored in a refrigerator (4 °C) overnight. The solid was formed and washed by methanol 
two times. The white solid was dried under vacuum to afford product with 45% yield. 
1H NMR (500MHz, CDCl3): δ  2.38 (s, 6H), 3.16–3.31 (m, 4H), 3.85 (q, 1H), 7.15 (d, 
4H), 7.18 (d, 4H), 7.64(d, 2H), 8.07 (d, 2H);  (Appendix 3) 
 
 





13C NMR (500MHz, CDCl3): δ 200.50, 137.24, 131.55, 131.15, 130.17, 129.86, 128.29, 
45.88, 36.41, and 21.10; (Appendix 4) 
ESI-MS (MeOH, 250oC): (-) m/z=435 [M-H]; (Appendix 5) 
  




A 1:1 methanol-deionized water solution (5 ml) was prepared in a 10 ml round 
bottom flask. To this solution, bis-sulfide (50 mg, 0.1145 mmol), and OXONE (0.422 g, 
0.687 mmol) were added The reaction mixture was stirred at RT for 24 h and monitored 
by TLC plate using EA/Hexane (v/v=1:1) mixed solvent. The mixture was poured into a 
separatory funnel and extracted with chloroform twice. Then, sufficient DI-water was 
added in order to dissolve the inorganic salts and extract twice. The organic extract was 
 
 





combined and extracted with Brine once. The solvent was removed under vacuum to 
afford the product in 60 % yield. 
1H NMR (500MHz, CDCl3): δ 2.49 (s, 6H), 3.48–3.66 (m, 4H), 4.40 (q, 1H), 7.37 (d, 
4H), 7.70–7.73 (m, 6H), 8.10 (d, 2H);  (Appendix 6) 





H5IO6 (22 mg, 0.0962 mmol, 2.1 equiv) was dissolved in acetonitrile (0.5 ml) by 
vigorous stirring at r.t., for 1 h. Then CrO3 (0.46 mg, 0.004581 mmol, 0.1 equiv) was 
added to the solution. The mixture was stirred at r.t. for 5min to give a clear orange 
solution. The H5IO6/CrO3 solution was then added dropwise over a period of 15 min to a 
solution of bis-sulfide (20 mg, 0.04581 mmol, 1 equiv) in ethyl acetate (1 ml) at -35℃. 
After the addition was completed, the reaction mixture was stirred at -35℃ for 1 h. The 
reaction was quenched by addition of saturated Na2SO3 solution.  
 
 





The reaction mixture contained the intermediate (17), the bis-sulfone (16) and 
starting material bis-sulfide (15). It’s more complicated than OXONE oxidation, so that 
OXONE was chose as oxidation agent at last. 
 




2-bromoethylamine hydrobromide (28 mg, 0.1374 mmol, 1.2 equiv) and DIEA 
(23 µl, 0.1374 mmol, 1.2 equiv) were added into 0.5ml DCM. Then, the mixture is stirred 
until the 2-bromoethylamine hydrobromide is completely converted into 2-
bromoethanamine, as monitored by TLC using DCM/MeOH (v/v=10:1) mixed solvent. 
 
 





In the meanwhile, bis-sulfide (15, 50 mg, 0.1145 mmol, 1 equiv), EDC (33 mg, 0.1718 
mmol, 1.5 equiv) and DMAP (2 mg, 0.01718 mmol, 0.15 equiv) are under vacuum for 30 
min. Then, argon was introduced first and followed by adding 0.5 ml DCM. After the bis-
sulfide has reacted to form the intermediate (monitored via TLC), a freshly prepared 
solution of 2-bromoethanamine was added. The reaction mixture is stirred at RT 
overnight, then poured into a separatory funnel and extracted with NaHCO3 twice and 
Brine once. The organic extract was combined and the solvent was removed. The mixture 
was purified by chromatography column using EA/Hexane (v/v=2:1) as eluting solvent 
combination. After drying under vacuum, the 39mg product was identifided as a mixture 
of N-(2-bromoethyl)-4-(3-(p-tolylthio)-2-((p-tolylthio)methyl)propanoyl)benzamide (18) 
and 2-(4-(3-(p-tolylthio)-2-((p-tolylthio)methyl)propanoyl)benzamido)ethan-1-ylium (22). 
 
1H NMR (500MHz, CDCl3): δ 7.88(d, 2H, 8.45Hz), 7.56(d, 2H, 8.45Hz), 7.13(d, 4H, 
7.75Hz), 7.05(d, 4H, 8.05Hz), 4.47(t, 2H, 9.63Hz), 4.10(t, 2H, 9.5Hz), 3.78(m, 1H, 
7.5Hz), 3.24(q, 2H, 7.03Hz), 3.15(q, 2H, 6.57Hz), 2.34(s, 6H). (Appendix 8) 
ESI-MS (MeOH, 250oC): (+) m/z = 462 [M - Br]+ ; (Appendix 9) 
Fab-MS :  (+) m/z = 462 [M - Br]+, 565[M+Na]+; (Appendix 10) 
 
 











Bis-sulfide 15 (20 mg, 0.04581 mmol, 1 equiv) dissolved in 1ml of DMF,  HBTU 
(28 mg, 0.0733 mmol, 1.6 equiv) and DIEA (15 µl, 0.09162 mmol, 2 equiv) were added 
together at 0 ℃ . The reaction mixture was stirred for 10 min before 2-
piperazinoethylamine (18 mg, 0.1374 mmol, 3 equiv) was introduced and the resulting 
mixture was stirred overnight at r.t..  The solvent was reduced under high vacuum, and 
the product was dissolved in DCM. The organic phase was washed with NaHCO3, brine 
and dried over anhydrous Na2SO4 and evaporated under vacuum. Since the desired 














In a flask equipped with a Dean-Stark trap and a condenser, a mixture of 2-
piperazinoethylamine (3.6 ml, 27.45 mmol) in 4-Methyl-2-pentanone(MIBK, 55 ml, 2 
L/M) was heated to reflux under argon. Reaction progress was monitored by recording 
the volume of water (0.5 ml) produced. After no more water was produced, the mixture 
was cooled to 0℃. Boc anhydride (6 g, 27.45 mmol) dissolved in a minimum of MIBK 
was then added dropwise to the flask. After stirring for 0.5 h at r.t., water (5.5 ml, 0.2 
L/M) was added. The aqueous layer was separated, and MIBK was evaporated under 
reduced pressure leading to the imine intermediate 25. Water (3 ml) and 2-propanol (28 
 
 





ml) were then added, and the mixture was heated to 50℃  until completion of the 
hydrolysis. Solvents were then distilled off providing the clean side product 27.  
1H NMR (500MHz, CDCl3): δ 1.46 (s, 18H, 1.90Hz), 2.39 (t, 4H, 5.02Hz), 2.46 (t, 2H, 
6.00Hz), 3.23(m, 2H, 5.05Hz), 3.42 (t, 4H, 5.2Hz); (Appendix 12) 
ESI-MS (MeOH, 250oC): (+)  m/z= 330 (M+H); (Appendix 13) 
 
4.16     Synthesis of Tert-butyl 4-(2-aminoethyl) piperazine-1-carboxylate (31)  
 
 
4-(3-(p-tolylthio)-2-((p-tolylthio)methyl)propanoyl)benzoic acid (15, 30mg, 
0.06871mmol, 1equiv) dissolved in 1ml of DMF was added HBTU (42mg, 0.1099mmol, 
1.6equiv) and DIEA (23μl, 0.1374mmol, 2equiv) at 0℃. The reaction mixture was stirred 
for 10mins before DO3tBu (3, 39mg, 0.07558mmol, 1.1equiv) was added. The resulting 
mixture was stirred overnight at r.t.. The solvent was reduced under high vacuum, and the 
product was dissolved in Chloroform. The organic phase was washed with DI water, 
 
 





brine and dried over anhydrous Na2SO4. The crude product was purified by 
chromatography column using Chloroform/Methanol (v/v=80:1) as eluting solvent 
combination. The solvent was removed under vacuum to afford the product in 12 % yield. 
 
1H NMR (500MHz, CDCl3): δ 7.57(d, 2H), 7.32(d, 2H), 7.16(d, 4H), 7.06(d, 4H), 
3.78(m, 3H), 3.58(t, 2H), 3.31(d, 4H), 3.25(q, 2H), 3.14(q, 2H), 3.09(s, 2H), 3.02(t, 2H), 









Chapter 5. Conclusion and future work 
The focus of this thesis was to synthesis suitable imaging agents with specific 
selectivity via two major strategies: (1) The synthesis of intercalators that allow the 
functionalization of proteins or peptides by reacting with disulfide bridges and (2) the 
synthesis of the chelator DOTA bearing a single functionality as well as the combination 
with the cell targeting entity folic acid that facilitates cell-specific cell uptake.  
The bis-disulfone (16) had been synthesized successfully. This molecule allows 
the specific functionalization of proteins or peptides by intercalating into disulfide bonds. 
A major drawback of such intercalators is their low solubility in aqueous solution and the 
necessity to use organic solvents such as DMSO or acetonirile, which strongly limits its 
application for the functionalization of proteins with relatively low stability. Therefore, 
novel, less lipophilic intercalator molecules had been designed and the reaction schemes 
for their preparation had been presented in this thesis. Despite various attempts, the 
targeted molecule was not synthesized and isolated.  
 In another section, the mono-functionalization of the compexing agent DOTA 
achieved was reported. Furthermore, a single ethynyl as well as maleimido group were 
also successfully incorporated into DOTA. This important building block allowed the 
 
 





straigntforward preparation of the  targeted Folate-DOTA conjugate  This “bifunctional 
molecule” offers folic acid as the cell targeting entity and  the chelator DOTA that can 
interact with a range of metal and transition metals e.g. gadolinium or gallium, which had 
been which could be used for PET or MRT imaging.  Such a molecule is highly attractive 
for imaging tissue of cancer cells that overexpress folic acid receptors such as certain 
breast cancers. Future experiments will be conducted with the company Siemens in order 
to further assess the suitability of this molecule for PET imaging of cancer tissue.   
It would be very appealing to conjugate the intercalator synthesised with a DOTA 
or folic acid group in order to decorate therapeutically relevant proteins or peptides with 
the additional functionalities. However, in this case water-solubility of the intercalator 
remains a key problem. Therefore, more water soluble intercalators need to be designed 
and synthesized  
The synthesis of the somatostatin DOTA conjugate was not achieved due to the 
degradation of the DOTA-intercalator, 31, under oxidizing condition. However, we 
proposed here an alternative synthetic strategy where the bis-disulfone (16) can be 
directly coupled with DO3tBu (3) (Scheme 15). The biological properties of the 
somatostatin-DOTA conjugate can then be investigated by in vitro experiments.  
 
 






 Scheme 15. Proposed synthetic route for somatostatin DOTA conjugate 
Based on this approach, a similar strategy can be used to label larger proteins 
bearing several disulfide bonds with the prospect of attaching a larger number of 
gadolinium complexes, which may ultimately improve the contrast and detection limit to 
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Appendix: NMR and MS Data 







2. ESI-Mass spectrum (-) of 1-[3-(4-carboxy-phenyl)-3-oxo-propyl]-piperidinium HCl (14) 
 
 






























































































































































































































































































































































































The MS spectrum of the first peak in LC profile 
 
The MS spectrum of the second peak in LC profile 
 
The MS spectrum of the third peak in LC profile 
 
30. The LC-IT-TOF-MS spectrum 
 
LC profile 


































The MS spectrum of the last peak in the LC profile 
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